Sana Biotechnology
Developing engineered cells as medicines to treat human diseases.
Company facts
- Founded
- 2018
- Employees
- 414
- Headquarters
- United States
- CEO
- Steve Harr, MD
- Type
- Public
- Listed
- NASDAQ: SANA
About
At Sana Biotechnology, we face the challenge of treating diseases that currently have no effective therapies. Our mission is to harness the properties of engineered cells to repair and control genes, ultimately creating innovative medicines that can address the underlying causes of these conditions. We believe that by leveraging advanced technologies in cellular and gene therapy, we can significantly improve patient outcomes. Our team is dedicated to understanding the complexities of each disease at a cellular and genetic level. This deep understanding is critical in developing tailored therapies that can effectively target and treat specific conditions. Our pipeline includes a range of product candidates, targeting various diseases including cancer, diabetes, and autoimmune disorders. By focusing on the repair and replacement of damaged or missing cells, we aim to provide transformative solutions that enhance the quality of life for patients.